StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Viridian Therapeutics, Inc.\DE's total debt was $20.89M at Sep 30, 2025. For fiscal 2024 it was $20.58M, up 1.9% from the year before. The highest annual figure on record is $20.58M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$20.58M+1.9%
FY2023Dec 31, 2023$20.21M–
FY2020Dec 31, 2020$0-100.0%
FY2019Dec 31, 2019$4.33M-45.9%
FY2018Dec 31, 2018$8.00M-19.3%
FY2017Dec 31, 2017$9.92M+251.8%
FY2016Dec 31, 2016$2.82M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$20.89M+1.8%
Q2 FY2025Jun 30, 2025$20.79M+1.6%
Q1 FY2025Mar 31, 2025$20.69M+2.4%
Q4 FY2024Dec 31, 2024$20.58M–
Q3 FY2024Sep 30, 2024$20.52M+397.3%
Q2 FY2024Jun 30, 2024$20.45M+280.1%
Q4 FY2023Dec 31, 2023$20.21M+496.2%
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2020Sep 30, 2020$4.13M-21.5%
Q2 FY2020Jun 30, 2020$5.38M-13.0%
Q1 FY2020Mar 31, 2020$3.39M-52.2%
Q4 FY2019Dec 31, 2019$4.33M-45.9%
Q3 FY2019Sep 30, 2019$5.26M-41.0%
Q2 FY2019Jun 30, 2019$6.18M-37.1%
Q1 FY2019Mar 31, 2019$7.09M-29.2%
Q4 FY2018Dec 31, 2018$8.00M-19.3%
Q3 FY2018Sep 30, 2018$8.91M+540.8%
Q2 FY2018Jun 30, 2018$9.82M+425.0%
Q1 FY2018Mar 31, 2018$10.02M+326.8%
Q4 FY2017Dec 31, 2017$9.92M+251.8%
Q3 FY2017Sep 30, 2017$1.39M–
Q2 FY2017Jun 30, 2017$1.87M–
Q1 FY2017Mar 31, 2017$2.35M–
Q4 FY2016Dec 31, 2016$2.82M–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?